Overcoming primary non-response to infliximab in ulcerative colitis: monocyte-derived PTGS2 as a therapeutic target.

Journal: Frontiers in immunology •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Pu D, Kang X, Gou L, et al. (2026). "Overcoming primary non-response to infliximab in ulcerative colitis: monocyte-derived PTGS2 as a therapeutic target.". Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1957588